MiNK Therapeutics (INKT) director Barbara Ryan sells 1,500 shares in open market

Rhea-AI Filing Summary

MiNK Therapeutics, Inc. director Barbara Ryan reported open-market sales of 1,500 shares of Common Stock. The transactions occurred on March 9–10, 2026 at prices between 10.1725 and 15.5652 per share. After these sales, she directly holds 20,406 shares of MiNK Therapeutics common stock.

According to the footnote, the shares sold were originally received as compensation for her services on the company’s Board of Directors, indicating the activity relates to monetizing equity-based director compensation rather than exercising options or derivatives.

Insights

Insider trading and governance analyst

Director Barbara Ryan sold 1,500 MiNK Therapeutics shares, a modest, compensation-related sale with remaining holdings intact.

Director Barbara Ryan executed four open-market sales of MiNK Therapeutics common stock totaling 1,500 shares on March 9–10, 2026. Prices ranged from 10.1725 to 15.5652 per share, and all trades involved non-derivative common stock.

Following these transactions, she directly holds 20,406 shares, so the sale represents only a portion of her disclosed equity position. A footnote specifies the shares were received as Board compensation, framing this as routine monetization of equity pay rather than an options exercise or complex derivative strategy.

There is no indication of derivative exercises or remaining derivative positions in this filing, and transaction data show a net-sell of 1,500 shares. In isolation, such director-level, compensation-linked selling is typically interpreted as routine liquidity activity rather than a thesis-changing signal for the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryan Barbara

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/09/2026		S		200	D	$10.1725	21,706	D
Common Stock(1)	03/10/2026		S		300	D	$15.2822	21,406	D
Common Stock(1)	03/10/2026		S		500	D	$15.5652	20,906	D
Common Stock(1)	03/10/2026		S		500	D	$15.3	20,406	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction reflects the sale of Common Stock received by Ms. Ryan as compensation for services rendered as a member of the MiNK Therapeutic Inc.'s Board of Directors.

	By: /s/ Austin Charette as Attorney-in-Fact for Barbara Ryan	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MiNK Therapeutics (INKT) director Barbara Ryan report?

Barbara Ryan reported selling 1,500 shares of MiNK Therapeutics common stock in open-market transactions. The sales occurred on March 9–10, 2026 and involved only non-derivative shares, with no option exercises or derivative conversions disclosed in this filing.

At what prices did Barbara Ryan sell MiNK Therapeutics (INKT) shares?

Barbara Ryan’s reported open-market sales of MiNK Therapeutics common stock were executed at prices between $10.1725 and $15.5652 per share. Each transaction is individually priced, reflecting normal trading executions rather than a single bulk trade at one uniform price.

How many MiNK Therapeutics (INKT) shares does Barbara Ryan hold after the reported sales?

After the reported transactions, Barbara Ryan directly holds 20,406 shares of MiNK Therapeutics common stock. This figure is disclosed in the filing as the total shares following the last reported sale and provides context that she retains a meaningful equity position.

What is the total number of MiNK Therapeutics (INKT) shares sold in this Form 4 filing?

The Form 4 shows that Barbara Ryan sold a total of 1,500 shares of MiNK Therapeutics common stock across four transactions. The filing’s transaction summary confirms 1,500 net sell shares and identifies all four trades as open-market sales of common stock.

Were Barbara Ryan’s MiNK Therapeutics (INKT) share sales related to equity compensation?

Yes. A footnote explains the shares sold were received as compensation for services rendered on MiNK Therapeutics’ Board of Directors. This indicates the transactions involve monetizing equity-based director compensation rather than exercising options or selling a large pre-existing investment stake.

Does Barbara Ryan’s Form 4 for MiNK Therapeutics (INKT) include any derivative securities activity?

No derivative securities activity is reported in this Form 4 for Barbara Ryan. The filing lists only non-derivative common stock transactions, and the derivative position summary is empty, indicating no option exercises, conversions, or other derivative trades in this disclosure.